KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
The Pharma Data
APRIL 8, 2021
Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. Merck has the industry’s largest immuno-oncology clinical research program.
Let's personalize your content